Account Wins from the 10/17/06 News Brief

Share this article:
Euro RSCG won ad duties for the osteoporosis drug Boniva following a review in which incumbent Saatchi & Saatchi Consumer Healthcare did not participate, Adweek.com reported. Havas-owned Euro RSCG beat out Omnicom’s BBDO in the final round of the review, the Adweek report said. Boniva is jointly marketed by GlaxoSmithKline and Roche and had a 2005 US media spend of $70 million, according to figures from Nielsen Monitor-Plus. Boniva competes against Eli Lilly’s Evista and Merck’s Fosamax and Procter & Gamble and Sanofi-Aventis’ Acotnel. Last month, a federal judge denied a motion filed by marketers of Actonel to halt Boniva advertising. P&G and Sanofi-Aventis charged that ads for Boniva falsely claimed the drug was proven to be more effective than Actonel. Judge Paul Crotty wrote: “There is no doubt that Boniva is a safe and effective drug which the FDA has approved for the treatment and prevention of osteoporosis in women… nor is Actonel superior to Boniva.”
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.